Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Amylyx Pharmaceuticals, Inc. (AMLX : NSDQ)

• Company Description    Amylyx Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. It focuses on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. Amylyx Pharmaceuticals Inc. is based in CAMBRIDGE, Mass. Number of Employees: 136

• Price / Volume Information    Yesterday's Closing Price: $13.58 Daily Weekly Monthly 20 Day Moving Average: 1,152,502 shares Shares Outstanding: 111.19 (millions) Market Capitalization: $1,509.91 (millions) Beta: -0.11 52 Week High: $18.61 52 Week Low: $4.64 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -21.59% -25.42% 12 Week -11.01% -17.73% Year To Date 12.42% 6.02%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 55 Cambridge Parkway Suite 6W - Cambridge,MA 02142 USA ph: 617-682-0917 fax: - investors@amylyx.com http://www.amylyx.com

• General Corporate Information    Officers Joshua B. Cohen - Co-Chief Executive Officer James M. Frates - Chief Financial Officer Paul Fonteyne - Director Daphne Quimi - Director Karen Firestone - Director Peer Information Amylyx Pharmaceuticals, Inc. (GSAC) Amylyx Pharmaceuticals, Inc. (CASIF) Amylyx Pharmaceuticals, Inc. (ALCD.) Amylyx Pharmaceuticals, Inc. (OMNN) Amylyx Pharmaceuticals, Inc. (CGPI.) Amylyx Pharmaceuticals, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 03237H101 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/06/26 Share - Related Items Shares Outstanding: 111.19 Most Recent Split Date: (:1) Beta: -0.11 Market Capitalization: $1,509.91 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.36 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.39 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 29.77% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/06/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 5.53 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 11.90% vs. Previous Quarter: -23.33% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -55.69 12/31/25 - -57.52 09/30/25 - -68.95 ROA 03/31/26 - -50.73 12/31/25 - -52.17 09/30/25 - -61.52 Current Ratio 03/31/26 - 17.85 12/31/25 - 14.27 09/30/25 - 13.70 Quick Ratio 03/31/26 - 17.85 12/31/25 - 14.27 09/30/25 - 13.70 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 2.46 12/31/25 - 2.78 09/30/25 - 3.02 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©